LTC2068874I2 - Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai - Google Patents

Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai

Info

Publication number
LTC2068874I2
LTC2068874I2 LTPA2016031C LTPA2016031C LTC2068874I2 LT C2068874 I2 LTC2068874 I2 LT C2068874I2 LT PA2016031 C LTPA2016031 C LT PA2016031C LT PA2016031 C LTPA2016031 C LT PA2016031C LT C2068874 I2 LTC2068874 I2 LT C2068874I2
Authority
LT
Lithuania
Prior art keywords
antibodies
methods
multiple myeloma
combination therapies
treating multiple
Prior art date
Application number
LTPA2016031C
Other languages
English (en)
Original Assignee
Abbvie Biotherapeutics Inc.
Dana-Farber Cancer Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38831279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2068874(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Biotherapeutics Inc., Dana-Farber Cancer Institute, Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of LTPA2016031I1 publication Critical patent/LTPA2016031I1/lt
Publication of LTC2068874I2 publication Critical patent/LTC2068874I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
LTPA2016031C 2006-08-07 2016-10-27 Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai LTC2068874I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
PCT/US2007/075403 WO2008019378A1 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (2)

Publication Number Publication Date
LTPA2016031I1 LTPA2016031I1 (lt) 2016-11-10
LTC2068874I2 true LTC2068874I2 (lt) 2018-11-12

Family

ID=38831279

Family Applications (4)

Application Number Title Priority Date Filing Date
LTEP13168383.1T LT2641601T (lt) 2006-08-07 2007-08-07 Daugybinės mielomos, naudojant kombinuotas terapijas, pagrįstas huluc63 su bortezomibu, gydymo būdai
LTPA2016031C LTC2068874I2 (lt) 2006-08-07 2016-10-27 Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
LTPA2016029C LTPA2016029I1 (lt) 2006-08-07 2016-10-27 Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
LTPA2016030C LTPA2016030I1 (lt) 2006-08-07 2016-10-27 Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP13168383.1T LT2641601T (lt) 2006-08-07 2007-08-07 Daugybinės mielomos, naudojant kombinuotas terapijas, pagrįstas huluc63 su bortezomibu, gydymo būdai

Family Applications After (2)

Application Number Title Priority Date Filing Date
LTPA2016029C LTPA2016029I1 (lt) 2006-08-07 2016-10-27 Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
LTPA2016030C LTPA2016030I1 (lt) 2006-08-07 2016-10-27 Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai

Country Status (24)

Country Link
US (4) US8632772B2 (lt)
EP (5) EP3115049A1 (lt)
JP (1) JP5340935B2 (lt)
CN (1) CN101686971B (lt)
AU (1) AU2007281684C1 (lt)
BR (1) BRPI0716647A2 (lt)
CA (1) CA2660356C (lt)
CY (5) CY1116247T1 (lt)
DK (2) DK2641601T3 (lt)
ES (2) ES2535437T3 (lt)
HK (1) HK1129853A1 (lt)
HR (2) HRP20150449T1 (lt)
HU (4) HUE029027T2 (lt)
IL (2) IL196919A (lt)
LT (4) LT2641601T (lt)
LU (3) LU93277I2 (lt)
MX (1) MX2009001441A (lt)
NL (1) NL300840I2 (lt)
NO (1) NO346835B1 (lt)
NZ (1) NZ574978A (lt)
PL (2) PL2068874T3 (lt)
PT (2) PT2068874E (lt)
SI (2) SI2641601T1 (lt)
WO (1) WO2008019378A1 (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3115049A1 (en) 2006-08-07 2017-01-11 AbbVie Biotherapeutics Inc. Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
PL2068930T3 (pl) 2006-08-07 2013-02-28 Abbvie Biotherapeutics Inc Kompozycje i sposoby wykorzystujące przeciwciało anty-CS1 do leczenia szpiczaka mnogiego
WO2009149021A2 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
NZ589880A (en) * 2008-06-16 2012-10-26 Immunogen Inc Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate
WO2010048298A1 (en) * 2008-10-21 2010-04-29 Proteolix, Inc. Combination therapy with peptide epoxyketones
EP2476438B1 (en) 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
EP2504703B1 (en) * 2009-11-24 2016-11-16 Celgene Corporation Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells
CN102241773B (zh) * 2010-05-13 2014-05-14 四川大学 抗骨髓瘤细胞多克隆抗体及其制备方法
EP2914278B1 (en) 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2015069703A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
WO2015069785A1 (en) * 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
MY176237A (en) * 2013-11-21 2020-07-24 Hoffmann La Roche Anti-alpha-synuclein antibodies and methods of use
SI3182996T1 (sl) * 2014-08-22 2023-04-28 Celgene Corporation Postopki zdravljenja multiplega mieloma z imunomodulatornimi spojinami v kombinaciji s protitelesi
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
US10365280B2 (en) 2014-10-02 2019-07-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
WO2016070089A2 (en) 2014-10-31 2016-05-06 Abbvie Biotherapeutics Inc. Anti-cs1 antibodies and antibody drug conjugates
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
SG11201708691VA (en) 2015-05-13 2017-11-29 Morphosys Ag Treatment for multiple myeloma (mm)
SI3313528T1 (sl) * 2015-06-29 2021-11-30 Bristol-Myers Squibb Company Imunoterapevtski režim odmerjanja, ki vsebujejo pomalidomid in protitelo anti-CS1 za zdravljenje raka
CN105688185B (zh) * 2016-03-13 2019-03-19 浙江药苑生物科技有限公司 一种用于治疗骨髓增生、骨癌的药物组合物及其用途
SG11201907923VA (en) * 2017-03-29 2019-09-27 Agency Science Tech & Res Anti oligosaccharide antibody
KR20200090193A (ko) * 2017-11-22 2020-07-28 힐스트림 바이오파마 인크. 보르테조밉을 포함하는 중합체 나노입자
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US20220390455A1 (en) 2019-11-05 2022-12-08 Bristol-Myers Squibb Company M-protein assays and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
DE69633668T2 (de) 1995-05-25 2006-03-09 Shimon Slavin Allogene zelltherapie für krebs infolge allogener stammzellen transplantation
ATE459357T1 (de) * 2002-05-17 2010-03-15 Celgene Corp Kombinationen zur behandlung von multiplem myelom
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US20090175866A1 (en) * 2004-11-04 2009-07-09 Avner Yayon Treatment of b-cell malignancies
US20080095768A1 (en) 2006-08-07 2008-04-24 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
EP3115049A1 (en) 2006-08-07 2017-01-11 AbbVie Biotherapeutics Inc. Combination therapies based on anti-cs1 antibodies for treating multiple myeloma
PL2068930T3 (pl) * 2006-08-07 2013-02-28 Abbvie Biotherapeutics Inc Kompozycje i sposoby wykorzystujące przeciwciało anty-CS1 do leczenia szpiczaka mnogiego

Also Published As

Publication number Publication date
JP2010500371A (ja) 2010-01-07
PL2641601T3 (pl) 2017-01-31
EP2641601B1 (en) 2016-07-06
NL300840I2 (lt) 2017-01-03
HUS1600044I1 (hu) 2016-12-28
SI2068874T1 (sl) 2015-06-30
CY2016037I1 (el) 2017-07-12
CY1117992T1 (el) 2017-05-17
SI2641601T1 (sl) 2016-11-30
CN101686971A (zh) 2010-03-31
EP2641601B8 (en) 2016-09-21
HK1129853A1 (en) 2009-12-11
LTPA2016029I1 (lt) 2016-11-10
HRP20161284T1 (hr) 2016-12-16
MX2009001441A (es) 2009-07-06
AU2007281684B2 (en) 2013-05-16
EP2641601A1 (en) 2013-09-25
LT2641601T (lt) 2016-10-10
US8632772B2 (en) 2014-01-21
EP2942057A1 (en) 2015-11-11
AU2007281684C1 (en) 2013-12-19
IL196919A0 (en) 2009-11-18
WO2008019378A1 (en) 2008-02-14
EP3115049A1 (en) 2017-01-11
US20170342150A1 (en) 2017-11-30
JP5340935B2 (ja) 2013-11-13
CA2660356A1 (en) 2008-02-14
LU93275I2 (fr) 2016-12-27
HUS1600045I1 (hu) 2016-12-28
US20160137735A1 (en) 2016-05-19
NZ574978A (en) 2012-08-31
CN101686971B (zh) 2013-09-11
CA2660356C (en) 2016-04-05
CY2016036I2 (el) 2017-07-12
EP2068874B1 (en) 2015-01-28
NO346835B1 (no) 2023-01-23
HRP20150449T1 (en) 2015-06-05
IL243933A0 (en) 2016-04-21
HUE029027T2 (en) 2017-01-30
HUS1600043I1 (hu) 2016-12-28
EP2641600A1 (en) 2013-09-25
LTPA2016031I1 (lt) 2016-11-10
US20140322201A1 (en) 2014-10-30
EP2068874A1 (en) 2009-06-17
NO20090968L (no) 2009-04-30
PT2068874E (pt) 2015-05-21
LTPA2016030I1 (lt) 2016-11-10
US20080152646A1 (en) 2008-06-26
PL2068874T3 (pl) 2015-06-30
LU93277I2 (fr) 2016-12-27
ES2589302T3 (es) 2016-11-11
CY2016036I1 (el) 2017-07-12
ES2535437T3 (es) 2015-05-11
LU93276I2 (fr) 2016-12-27
CY2016038I1 (el) 2017-07-12
BRPI0716647A2 (pt) 2017-05-16
PT2641601T (pt) 2016-10-14
AU2007281684A1 (en) 2008-02-14
DK2641601T3 (en) 2016-08-22
IL196919A (en) 2016-03-31
CY1116247T1 (el) 2017-02-08
DK2068874T3 (da) 2015-04-27

Similar Documents

Publication Publication Date Title
LTPA2016030I1 (lt) Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai
LTPA2017040I1 (lt) Antikūnai prieš CD38 antigeną, skirti išsėtinės mielomos gydymui
LTPA2020536I1 (lt) Nauji anti-CD38 antikūnai, skirti vėžio gydymui
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2225280T3 (da) Bivalente, bispecifikke antistoffer
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
DK3401334T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
NO344963B1 (no) Humanisert antistoff
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
DK2781593T3 (da) Fremgangsmåde til behandling af methanemissioner
DK3312197T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK2131860T3 (da) Anti-sclerostin-antistoffer
BRPI0814466A2 (pt) Método.
DK2019840T3 (da) Antagonist anti-human CD40 monoklonalt antistof.
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
BRPI0818865A2 (pt) Anticorpos monoclonais contra proteína c ativada.
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
DK2012814T3 (da) Fremgangsmåder til behandling af autoimmunsygdomme
DK2131841T3 (da) Fremgangsmåder til behandling af akut smerte
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer
BRPI0718324A2 (pt) Métodos para o tratamento de depressão.
DK1982178T3 (da) Fremgangsmåder til behandling af affektbetonede lidelser
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.